Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nepicastat oral

Drug Profile

Nepicastat oral

Alternative Names: DBH inhibitor programme; DβH inhibitor programme; Nepicastat hydrochloride; SYN-117

Latest Information Update: 02 Mar 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Biotie Therapies Corp.
  • Class Antiparkinsonians; Anxiolytics; Drug withdrawal therapies; Imidazoles; Neuropsychotherapeutics; Small molecules; Thiones
  • Mechanism of Action Dopamine beta hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cocaine abuse; Parkinson's disease; Post-traumatic stress disorders

Most Recent Events

  • 27 May 2014 The National Institute on Drug Abuse & Biotie complete enrolment in a phase II trial for Cocaine abuse in USA (NCT01704196)
  • 22 May 2014 Phase-II development is ongoing in USA
  • 13 May 2013 Biotie Therapies initiates enrolment in a phase II trial for Cocaine abuse in USA
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top